The Shkreli scandal leaves a big mess for biotech to clean up

John Carroll

The industry now has to deal with the fact that drug pricing has taken center stage in presidential politics. And the story of Daraprim, Martin and price gouging left a wound that will take some time to heal. is not Shkreli, of course, but it will have to prove it now with some sensible discussions on innovation and pricing.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS